X
Xbiome
China's first AI-driven microbiome drug development company
About Xbiome
Xbiome, established in 2017, operates at the intersection of artificial intelligence and microbiome-based therapeutics. The company was founded by Dr. Tan Yan, who serves as CEO, and Dr. Shi Yan, the Chief Scientific Officer. Dr. Tan's background includes a Ph.D. from Cornell University and experience at the Boston Consulting Group, while Dr. Shi brings expertise from his time as a postdoctoral researcher at the University of Pennsylvania and work at Johnson & Johnson, grounding the company's leadership in both business strategy and deep scientific knowledge.
Read full description
The firm focuses on developing drugs by targeting the gut microbiome, which is implicated in a wide range of diseases. Xbiome's core is its proprietary platform, X-Evolution, which integrates AI, bioinformatics, and gut microbiome technologies to accelerate the discovery and development of new drugs. This data-driven approach aims to improve the success rate compared to traditional drug discovery paradigms. The company's business model revolves around the research, development, and eventual commercialization of these novel therapeutics.
Xbiome's product pipeline is advancing with several candidates in development. Its leading program, M-001, is designed to treat moderate to severe ulcerative colitis and has progressed to Phase II clinical trials in China and received IND clearance from the FDA in the United States. Another key candidate, M-007, an orally administered live biotherapeutic product, has also received FDA IND clearance for the treatment of acute GvHD. These milestones underscore the company's progress in translating its AI-driven research into tangible clinical assets targeting inflammatory and immune-related conditions.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Shenzhen, China
- Employees
- 50
- Open positions
- None listed
- Dealroom signal
- 72.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Tech for Biotech and Pharma, AI Drug Discovery, Hard Tech, AI Applications, DT and LS
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Xbiome.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| OtherOther financing | Dec 2021 | $0 | — | Primavera Capital Group · Hike Capital · Sky9 Capital | — |
| SERIES B✓Equity / VC | Nov 2020 | $20M | $80M | Yimei Capital · Primavera Capital Group · 5Y Capital · Legend Capital | — |
Growth signals
Latest recorded traffic for Xbiome is 160 monthly website visits, down 50% over the last three months. Xbiome's team grew 2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Gaorong Ventures
Legend Capital
5Y Capital- YCYimei Capital
Primavera Capital Group
Other known investors2 additional known investors
Hike Capital
Sky9 Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xbiome on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xbiome’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.